Logo

PharmaShots Weekly Snapshots (June 13– 17, 2022)

Share this
PharmaShots Weekly Snapshots (June 13– 17, 2022)

PharmaShots Weekly Snapshots (June 13– 17, 2022)

Sierra Oncology Reports NDA Submission of Momelotinib to the US FDA for the Treatment of Myelofibrosis

Published: June 17, 2022 | Tags: Sierra Oncology, Momelotinib, Myelofibrosis, NDA, US, FDA,

Basilea and Pfizer Collaborated to Commercialize Cresemba for Invasive Aspergillosis and Mucormycosis

Published: June 17, 2022 | Tags: Basilea, Pfizer, Cresemba , Invasive Aspergillosis, Mucormycosis,

Addex Discontinue P-IIb/III Study of Dipraglurant for the Treatment of Dyskinesia Associated With Parkinson’s Disease

Published: June 17, 2022 | Tags: Addex, Dipraglurant, Parkinson’s Disease, P-IIb/III Study

Cordis’ Radianz Radial Peripheral System Used in First-in-Human Procedure for Vascular Disease

Published: June 17, 2022 | Tags: Cordis, Radianz Radial Peripheral System, Vascular Disease,

Checkpoint Therapeutics Reports Interim Results of Cosibelimab in Registration-Enabling Trial for Locally Advanced Cutaneous Squamous Cell Carcinoma

Published: June 17, 2022 | Tags: Checkpoint Therapeutics, Cosibelimab, Cutaneous Squamous Cell Carcinoma

Rhythm Receives the US FDA’s Approval for Imcivree (setmelanotide) sNDA to Treat Bardet-Biedl Syndrome

Published: June 17, 2022 | Tags: Rhythm, Imcivree, Bardet-Biedl Syndrome, Regulatory, US, FDA, sNDA

Genentech’s Crenezumab Fails to Meet Primary Endpoints in Alzheimer’s Disease with Cognitively Unimpaired Patients

Published: June 16, 2022 | Tags: Genentech, Crenezumab, Alzheimer’s Disease, Cognitively Unimpaired

Kintara’s VAL-083 Receives the US FDA’s Fast Track Designation for the Treatment of Newly Diagnosed Glioblastoma

Published: June 16, 2022 | Tags: Kintara, VAL-083, US, FDA, Fast Track Designation, Glioblastoma

Hansa Biopharma's Idefirix (imlifidase) Receives NICE Recommendation as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients

Published: June 16, 2022 | Tags: Hansa Biopharma, Idefirix, imlifidase, NICE, Desensitization, Kidney Transplant

Faron Reports 12-Month Survival Results of Bexmarilimab in P-I/II (MATINS) Study for the Treatment of Solid Tumor

Published: June 16, 2022 | Tags: Faron, Bexmarilimab, P-I/II, MATINS Study, Solid Tumor

Adaptive Launches T-Detect Test for the Detection of Early Lyme Disease

Published: June 16, 2022 | Tags: Adaptive, T-Detect Test, Early Lyme Disease

Exelixis Entered into an Option and License Agreement with BioInvent to Develop Novel Antibody-Based Immuno-Oncology Therapies

Published: June 16, 2022 | Tags: Exelixis, Option, License, Agreement, BioInvent, Antibody-Based, Immuno-Oncology

Alchemedicine Entered into an Exclusive License Agreement with Asahi Kasei Pharma for Endothelin A Receptor Antagonist to Treat Chronic Kidney Disease

Published: June 15, 2022 | Tags: Alchemedicine, Asahi Kasei Pharma, Endothelin A, Receptor, Antagonist

The EMA and HMA Acquired Big Data Strategy to Folster Veterinary Therapies in the EU

Published: June 15, 2022 | Tags: EMA, HMA, Big Data Strategy, Veterinary, EU

Xenco Medical Expanded its ASC Surgical Device Portfolio with the Launch of Multilevel CerviKit

Published: June 15, 2022 | Tags: Xenco Medical, ASC, Surgical Device, Portfolio, Multilevel CerviKit

Pfizer Reports Updated Results of Paxlovid (nirmatrelvir and ritonavir) in the P-II/III (EPIC-SR) Trial for the Treatment of COVID-19

Published: June 15, 2022 | Tags: Pfizer, Paxlovid, nirmatrelvir, ritonavir, P-II/III, EPIC-SR Trial, COVID-19

Vyluma Entered into an Exclusive License Agreement with Théa for the Registration and Commercialization of NVK002 to Treat Myopia

Published: June 15, 2022 | Tags: Vyluma, Théa, NVK002, EU, Canada, Latin America, Myopia

MorphoSys Entered into a License Agreements with HIBio to Develop and Commercialize Felzartamab and MOR21 for Autoimmune and Inflammatory Diseases

Published: June 15, 2022 | Tags: MorphoSys, HIBio, Felzartamab, MOR21, Autoimmune, Inflammatory Diseases

Clover Reports the First Patient Dosing of SCB-2019 as a Heterologous Booster in P-III Trial for the Treatment of COVID-19

Published: June 14, 2022 | Tags: Clover, SCB-2019, Heterologous Booster, P-III Trial, COVID-19

Innovent Reports the NMPA Acceptance of NDA for Tafolecimab to Treat Primary Hypercholesterolemia and Mixed Dyslipidemia

Published: June 14, 2022 | Tags: Innovent, NMPA, NDA, Tafolecimab, Primary Hypercholesterolemia, Mixed Dyslipidemia

Eli Lilly and Incyte’ Olumiant (baricitinib) Receives the US FDA’s Approval as First-In-Disease Systemic Treatment for Adults with Severe Alopecia Areata

Published: June 14, 2022 | Tags: Eli Lilly, Incyte, Olumiant, baricitinib, US, FDA, Approval, Alopecia Areata

Lilly Entered into an Exclusive License Agreement with D. E. Shaw Research to Develop and Commercialize DES-7114 for Immunological and Inflammatory Diseases

Published: June 14, 2022 | Tags: Lilly, D. E. Shaw Research, DES-7114, Immunological, Inflammatory Diseases

Alnylam’s Amvuttra (vutrisiran) Receives the US FDA’s Approval for Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis

Published: June 14, 2022 | Tags: Alnylam, Amvuttra, vutrisiran, US, FDA, Approval, Polyneuropathy, Hereditary, Transthyretin-Mediated Amyloidosis

Organon Entered into an Agreement with Henlius to Commercialize Perjeta (pertuzumab) and Prolia/Xgeva (denosumab) Biosimilars

Published: June 14, 2022 | Tags: Organon, Henlius, Perjeta, pertuzumab, Prolia, Xgeva, denosumab Biosimilars

Merck Reports the US FDA Acceptance of sBLA for Review of Keytruda (pembrolizumab) as Adjuvant Therapy for Stage IB-IIIA Non-Small Cell Lung Cancer

Published: June 13, 2022 | Tags: Merck, US, FDA, sBLA, Keytruda, pembrolizumab, Stage IB-IIIA, Non-Small Cell Lung Cancer

Cogent Presents Results of Bezuclastinib in P-II (APEX) Trial for the Treatment of Advanced Systemic Mastocytosis at EHA 2022

Published: June 13, 2022 | Tags: Cogent, Bezuclastinib, P-II, APEX Trial, Systemic Mastocytosis, EHA, 2022

Agios Presents Results of Pyrukynd (mitapivat) in P-III (ACTIVATE) Study for the Treatment of PK Deficiency at EHA 2022

Published: June 13, 2022 | Tags: Agios, Pyrukynd, mitapivat, P-III, ACTIVATE Study, PK Deficiency, EHA, 2022

Zavation’s eZspand Lateral Lumbar Interbody Fusion Device Receives the US FDA’s Clearance for the Treatment of Degenerative Disc Disease

Published: June 13, 2022 | Tags: Zavation, eZspand Lateral, Lumbar Interbody Fusion Device, US, FDA, Clearance Degenerative Disc Disease

Janssen Presents New and Updated Results of Imbruvica (ibrutinib) in P-II (CAPTIVATE) Study as Fixed-Duration Combination Regimen for CLL and SLL at EHA 2022

Published: June 13, 2022 | Tags: Janssen, Imbruvica, ibrutinib, P-II, CAPTIVATE Study, CLL, SLL, EHA, 2022

Daiichi Sankyo Presents Results of Quizartinib in P-III (QuANTUM-First) Study for the Treatment of FLT3-ITD Positive Acute Myeloid Leukemia at EHA2022

Published: June 13, 2022 | Tags: Daiichi Sankyo, Quizartinib, P-III, QuANTUM-First Study, FLT3-ITD, Acute Myeloid Leukemia, EHA2022

Related Post:  PharmaShots Weekly Snapshots (June 06– 10, 2022)


Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions